BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
BioLargo, Inc. (BLGO) reported Q3 2026 results with revenue at $1.09M, down 1% YoY, and net loss at $3.82M, down 47% YoY. Clyra Medical, a subsidiary, drove 57% of the nine-month net loss. The company launched consumer products under the 'barebird' brand and is preparing for a 2027 product line rollout. BioLargo's AEC PFAS treatment is being validated and has seen increased interest from potential partners.
How this was made
The 30-second read
Why it matters
The quarter adds new datapoints on revenue mix (service up, product down), consolidated loss drivers (Clyra), and liquidity (operating cash burn funded largely by Clyra debt), while reiterating a 2027 commercialization inflection.
Market read
Traders get a fresh quarterly snapshot plus concrete commercialization milestones and funding details that shape expectations for a 2027 sales inflection.
What to watch
Debt financing at the subsidiary level and reliance on milestones and distributor agreements could increase refinancing or execution risk if rollout timing slips.
Background
BioLargo is an OTC-listed cleantech and life sciences company with commercialization efforts spanning Clyra Medical (wound irrigation), AEC PFAS treatment, and a consumer odor brand using CupriDyne technology.
Ticker impact
BioLargo reported Q3 2026 results and said Clyra Medical is funding commercialization ahead of a 2027 national rollout, shifting spending toward sales.
Likely modest sentiment support as traders price in 2027 commercialization progress, offset by ongoing losses and cash burn.
The article provides fresh quarterly financials, details on Clyra’s distributor buildout and debt-funded commercialization, and notes no quarterly earnings call, which can reduce near-term catalysts while keeping the 2027 narrative central.
Market effects
Highlights continued commercialization investment in PFAS treatment and wound care distribution, reinforcing investor attention on execution risk in cleantech/life-sciences commercialization.
No clear regional market catalyst beyond the company’s shareholder meeting location.
PFAS treatment demand narrative is global, but the article’s specifics are company-level and US-focused distribution.
Counterpoint
The 2027 breakout framing may be optimistic given nine-month revenue contraction and operating cash burn, so the market may discount the narrative until clearer commercial traction appears.
Key entities
- companyBioLargo, Inc.
OTCQX-listed cleantech and life sciences company reporting Q3 2026 results and commercialization updates.
- business_unitClyra Medical
Wound irrigation commercialization engine accounting for most consolidated net loss due to pre-2027 investment.
- subsidiaryBioLargo Equipment Solutions & Technologies, Inc.
Entity associated with AEC PFAS treatment monitoring and commercialization discussions.
- subsidiaryBioLargo CPG LLC
New consumer products vehicle for the barebird brand using CupriDyne Clean technology.




